David Groff

Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma

Ji Youn Lee, R. Mach, J. Maris, 2022, Communications Biology.

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

S. Seaman, J. Maris, B. Teicher, 2021, Clinical Cancer Research.

RETRACTED ARTICLE: Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs

Amber K Weiner, S. Stevanović, D. Dimitrov, 2021, Nature.

BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma

J. Maris, A. Shlien, S. Diskin, 2023, bioRxiv.

Targeting of intracellular oncoproteins with peptide-centric CARs

J. Maris, N. Sgourakis, S. Tripathi, 2023, Nature.

Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma

J. Maris, M. Samanta, D. Pryma, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.